Vax on, vax off... AstraZeneca stock dropped 5% for the week on two pieces of not-so-hot news. First, it announced that its Covid-19 vaccine was 70% effective on average. That sounds solid — until you compare it to Pfizer and Moderna's 95% effectiveness rates. Then, AstraZeneca acknowledged a key mistake in its trials, which made experts question the reliability of its data. Oxford University, which jointly made the vaccine, says more data is needed to determine its efficacy and safety.
Peace, Love... the Gap? Oversized hoodie legend Gap wasn't feeling it last week. Its stock plunged 11% on worse-than-expected quarterly earnings. Gap's Old Navy brand saw strong growth, and its athleisure brand Athleta (unsurprisingly) performed particularly well — sales soared a record 35% on the leggings life. Despite a 61% jump in online sales, Gap's profit missed estimates because it boosted marketing spend last quarter.